SAN DIEGO, April 22 /PRNewswire/ -- Valor Medical's CEO, H. Clark Adams, announced today that Valor's European clinical trial was finalized with 30 patients treated. Mr. Adams stated, "The trial took longer than expected because there are current approved therapies which were used as a first line of therapy. Patients who were enrolled to be treated with Valor's Neucrylate were not always acceptable candidates for these standard-of-care therapies. Basically, the aneurysms in the trial patients were uncommonly difficult and could not be treated with coil therapy, but Neucrylate AN demonstrated that even the most difficult aneurysms could be treated in a time efficient manner.
